Skip to Content

Thermo Fisher Scientific Inc TMO

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Thermo Fisher Scientific Delivers Yet Another Strong, COVID-19-Backed Quarter

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We anticipate a moderate increase to our fair value estimate of wide-moat Thermo Fisher Scientific as we update our model following the release of second-quarter results. Total revenue grew 34% year over year for the quarter to $9.27 billion, marking the fourth consecutive quarter of over 30% growth year over year. Revenue continues to be inflated due to the COVID-19 pandemic response, which accounted for $1.9 billion of total revenue. With the second quarter providing a strong close for the first half of the year, management is raising revenue and adjusted earnings per share guidance for fiscal 2021 to $35.90 billion and $22.07, respectively.

Read Full Analysis

Company Profile

Business Description

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).

Contact
168 Third Avenue
Waltham, MA, 02451
T +1 781 622-1000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Aggressive Growth
Employees 75,000

Related